A Phase II trial of Recce Pharmaceutical’s topical skin infection gel has ‘exceeded expectations’, with 93% of patients achieving the primary efficacy endpoint. The Australian company’s ...

Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the Australian biotech to point to the anti-infective's potential to counter ...

Recce Pharmaceuticals has shared positive data from a mid-stage study of its RECCE 327 topical gel (R327G) in acute bacterial skin and skin structure infections (ABSSSIs). The open-label phase 2 trial ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. A successful phase II clinical trial has taken place, assessing efficacy and safety of R327G in ...

SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it ...

A successful phase II clinical trial has taken place, assessing efficacy and safety of R327G in patients with acute bacterial skin and skin structure infections Recce said objectives exceeded with ...